<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466401</url>
  </required_header>
  <id_info>
    <org_study_id>HP-5-155-S</org_study_id>
    <nct_id>NCT00466401</nct_id>
  </id_info>
  <brief_title>Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation</brief_title>
  <official_title>Phase 4 Study on Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation In Hypercholesterolemic Patients on Simvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ziv Hospital</source>
  <brief_summary>
    <textblock>
      The aim of our study is to Estimate the reduction of LDL by ezetimibe in hypercholesterolemic
      patients on simvastatin.Investigate the effect of LDL lowering by ezetimibe on platelet
      activity and LDL tendency to peroxidation in hypercholesterolemic patients on simvastatin
      therapy

      The hypothesis is that:

        1. LDL lowering by ezetimibe on-top of simvastatin in patients on fixed dose of simvastatin
           can reduce platelet aggregation, due to the potential decreasing of cholesterol content
           in the platelet membranes.

        2. LDL lowering by ezetimibe can lower LDL tendency to peroxidation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hypercholesterolemic patients on stable simvastatin dose for at least one month.

          2. Age ≥18 years on stable AHA step 1 diet.

          3. Patients without CHD or with one risk factors ; LDL &gt; 130 mg/dL and for Patients with
             CHD or CHD risk equivalent(clinical manifestations of non-coronary forms of
             atherosclerotic disease) or with 2 risk f actors (cigarette smoking, hypertension (BP
             ≥140/90 mm Hg or on antihypertensive medication), low HDL cholesterol (&lt;40 mg/dL),
             family history of premature CHD;LDL&gt;100 mg/dL

          4. Patients `on at least simvastatin treatment of 20 mg per day.

          5. CPK, ALT and AST &lt; 1.5 X upper limit of normal at baseline.

        Exclusion Criteria:

          1. Women currently receiving cyclical hormones.

          2. Treatment with psyllium, other fiber based laxatives, phytosterol margarines, or other
             OTCs that affect serum lipids, unless treated with a stable regimen for &gt; 6 weeks and
             the patient agrees to continue this regimen for the duration of the trial.

          3. Oral corticosteroids unless used as replacement therapy for pituitary/adrenal disease
             and a stable regimen for at least 6 weeks.

          4. Lipid lowering agents including fish oils and QUESTRAN taken within 6 weeks.

          5. Active coronary heart disease: unstable angina, acute myocardial infarction, CABG or
             PTCA within the last 3 months.

          6. Women with childbearing potential unless on safe contraception.

          7. Psychiatric disease with defect in judgement.

          8. Severe renal or hepatic disease.

          9. Uncontrolled hypo- or hyperthyroidism.

         10. Contraindication for ezetimibe or simvastatin treatment. The patients will continue on
             their treatment with simvastatin for 6 weeks, and then the patients will be treated by
             the same dose of simvastatin combined with ezetimibe 10 mg/day for other 6 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamah Hussein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal Medicine Department A ,Ziv Goverment Hospital</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP; Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001 Aug;23(8):1209-30. Erratum in: Clin Ther 2001 Sep;23(9):1601.</citation>
    <PMID>11558859</PMID>
  </reference>
  <reference>
    <citation>Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002 Dec 18;40(12):2125-34.</citation>
    <PMID>12505224</PMID>
  </reference>
  <reference>
    <citation>van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes. 2001 Jun;50(6):1330-5.</citation>
    <PMID>11375333</PMID>
  </reference>
  <reference>
    <citation>Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E; Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003 Dec 15;92(12):1414-8.</citation>
    <PMID>14675576</PMID>
  </reference>
  <reference>
    <citation>Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2032-8.</citation>
    <PMID>11742881</PMID>
  </reference>
  <reference>
    <citation>Lavy A, Brook GJ, Dankner G, Ben Amotz A, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 1991 Aug;40(8):794-9.</citation>
    <PMID>1861629</PMID>
  </reference>
  <reference>
    <citation>Hussein O, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology. 2001 Aug;8(1):21-28.</citation>
    <PMID>11476969</PMID>
  </reference>
  <reference>
    <citation>Surya II, Akkerman JW. The influence of lipoproteins on blood platelets. Am Heart J. 1993 Jan;125(1):272-5. Review.</citation>
    <PMID>8380241</PMID>
  </reference>
  <reference>
    <citation>Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 1989 Apr;76(2-3):117-24.</citation>
    <PMID>2730708</PMID>
  </reference>
  <reference>
    <citation>Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol. 1997 Jul;44(1):77-83.</citation>
    <PMID>9241100</PMID>
  </reference>
  <reference>
    <citation>Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med. 1983 Aug;30(1):111-8.</citation>
    <PMID>6626183</PMID>
  </reference>
  <reference>
    <citation>Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003 Apr;24(8):729-41.</citation>
    <PMID>12713767</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

